COVID-19

Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA

Staff August 20, 2026

Leading cognitive-disorders specialist, Dr. William Shankle, will discuss vascular cognitive impairment, vascular dementia and the proposed clinical trial of VesCell™...

Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio

Staff August 19, 2026

Positive DRDC findings support the next phase for bucillamine as Revive plans to pursue government-backed development opportunities, expand intellectual property...

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

Staff August 18, 2026

SHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

Staff August 10, 2026

SHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA

Staff August 5, 2026

mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved productCompany expects supply to be available in select retailers in...

Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna’s Investigational Vaccine Against Bundibugyo Ebolavirus

Staff August 4, 2026

Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines...

Manufacturing PMI® at 55.6%; July 2026 ISM® Manufacturing PMI® Report

Staff August 3, 2026

New Orders Growing; Production Growing; Employment Growing; Supplier Deliveries Slowing; Raw Materials Inventories Growing; Customers' Inventories Too Low; Prices Increasing;...

DataMeds AI’s Corexa Pharmacy Launches Tollo Health’s Tollovid(R) and Galactovid(TM)

Staff July 31, 2026

Launch targets acute viral infection and Long COVID markets through www.CorexaRx.com/Store TAMPA, FL / ACCESS Newswire / July 31, 2026...

Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026

Staff July 30, 2026

Calgary, Alberta--(Newsfile Corp. - July 30, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased...

Hemostemix’ Longevity Phase I Clinical Trial Leveraging VesCell(TM)’s Excellent Results

Staff July 28, 2026

Calgary, Alberta--(Newsfile Corp. - July 28, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"),...

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

Staff July 28, 2026

SHELTON, CT / ACCESS Newswire / July 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc

Staff July 23, 2026

Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2, in the...

ENT Experts in Philadelphia Share Preventive Tips for Reducing Sinus and Ear Issues During Flu Season

Staff July 22, 2026

Becker ENT & Allergy shares preventive guidance for managing seasonal respiratory illness and protecting sinus and ear health. PHILADELPHIA, PA...

As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola

Staff July 22, 2026

SHELTON, CT / ACCESS Newswire / July 22, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

Apollo Neuroscience Announces Publication of Landmark Clinical Study Demonstrating Apollo Wearable Use Yields an Average of 46 More Minutes of Sleep Per Night

Staff July 16, 2026

Clinical study of 475,000 nights of sleep data across 935 people over 3 years found Apollo use was associated with...

Coalition for Health AI (CHAI) Launches PULSE, a National Initiative to Help Public Health Agencies Responsibly Implement AI at Scale

Staff July 16, 2026

2,000 public health practitioners will join dedicated communities of practice and cross-jurisdiction peer networks, through enterprise licenses donated by Anthropic...

Astrana Health ACOs Deliver $120.4 Million in Gross Shared Savings in 2024 Performance Year

Staff July 13, 2026

All Eight ACOs Achieve Net Shared SavingsALHAMBRA, Calif., July 13, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with...

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo

Staff July 13, 2026

SHELTON, CT / ACCESS Newswire / July 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain

Staff July 8, 2026

Calgary, Alberta--(Newsfile Corp. - July 8, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company"), the leading...

Research Analyst Report on NanoViricides Rates Company “Outperform”; Separately, A “Fireside Chat” Interview of the Company’s President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily